ProfileGDS5672 / 216419_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
OrganismHomo sapiens


control bevacizumab dibenzazepine GSM958322 GSM958323 GSM958324 GSM958328 GSM958329 GSM958330 GSM958325 GSM958326 GSM958327 52% 52% 52% 53% 53% 52% 52% 52% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM958322U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2]3.1476852
GSM958323U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2]3.0967352
GSM958324U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2]3.1476852
GSM958328U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2]3.1970153
GSM958329U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2]3.1476853
GSM958330U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2]3.1439652
GSM958325U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2]3.1445752
GSM958326U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2]3.1664252
GSM958327U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2]3.1476853